-
公开(公告)号：US10322107B2
公开(公告)日：2019-06-18
申请号：US15539061
申请日：2015-12-18
申请人： Nektar Therapeutics
IPC分类号： A61K31/4025 , C07D213/71 , C07D231/18 , C07D333/34 , C07D239/60 , C07D261/10 , C07D207/12 , C07D207/14 , C07D295/13 , C07D295/135 , C07D207/04
摘要： Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
-
公开(公告)号：US20190071454A1
公开(公告)日：2019-03-07
申请号：US16182387
申请日：2018-11-06
申请人： Nektar Therapeutics
发明人： Pankaj Sharma , Vijay Kumar Khatri , Xuyuan Gu , Yuan Song , Michael Lixin Shen , Jennifer Riggs-Sauthier , Neel K. Anand , Antoni Kozlowski , Aleksandrs Odinecs , Timothy A. Riley , Zhongxu Ren , YongQi Mu , Xiaoming Shen , Xuejun Yuan , Natalia Aurrecoechea , Donogh John Roger O'Mahony , Bo-Liang Deng
IPC分类号： C07D498/04 , A61P33/06 , A61P25/28 , A61P25/02 , A61K31/496 , A61K31/53 , C07D401/04 , C07D405/12 , C07D403/12 , C07D401/12 , C07D253/075 , C07D403/04 , C07D471/10
摘要： The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
-
公开(公告)号：US20180127375A1
公开(公告)日：2018-05-10
申请号：US15569726
申请日：2016-05-05
申请人： Nektar Therapeutics
发明人： Neel K. Anand , Natalia Aurrecoechea , Lin Cheng , Bo-Liang Deng , Donogh John Roger O'Mahony , YongQi Mu , Erik Krogh-Jespersen
IPC分类号： C07D221/28 , C07D401/12 , C07D417/12 , C07D407/04 , C07D471/08 , C07D513/08 , A61P25/04
CPC分类号： C07D221/28 , A61P25/04 , C07D401/12 , C07D407/04 , C07D407/12 , C07D417/12 , C07D471/08 , C07D513/08
摘要： The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
-
公开(公告)号：US09937266B2
公开(公告)日：2018-04-10
申请号：US15164607
申请日：2016-05-25
申请人： Nektar Therapeutics
IPC分类号： C07C231/12 , C07C237/44 , A61K47/48 , A61K31/166
CPC分类号： A61K47/59 , A61K31/166 , A61K47/60 , C07C231/12 , C07C237/44
摘要： The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
-
25.发明申请公开(公告)号：US20170368029A1
公开(公告)日：2017-12-28
申请号：US15539061
申请日：2015-12-18
申请人： Nektar Therapeutics
IPC分类号： A61K31/4025 , C07D231/18 , C07D207/04 , C07D213/71 , C07D333/34 , C07D261/10
CPC分类号： A61K31/4025 , C07D207/04 , C07D207/12 , C07D207/14 , C07D213/71 , C07D231/18 , C07D239/60 , C07D261/10 , C07D295/13 , C07D295/135 , C07D333/34
摘要： Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
-
公开(公告)号：US12054553B2
公开(公告)日：2024-08-06
申请号：US16610401
申请日：2018-05-02
申请人： Nektar Therapeutics
发明人： Saul Kivimae , Marlene Hennessy , Neel K. Anand , Haiying Cai , Bo-Liang Deng , Zhongxu Ren , Bhalchandra V. Joshi
CPC分类号： C07K16/2878 , A61K31/4745 , A61K47/60 , A61P35/00 , C07K14/55 , A61K2039/505
摘要： Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.
-
公开(公告)号：US12030940B2
公开(公告)日：2024-07-09
申请号：US16639520
申请日：2018-08-17
申请人： Nektar Therapeutics
发明人： Jonathan Zalevsky , Neel K. Anand , Haiying Cai , Bo-Liang Deng , Zhongxu Ren , Bhalchandra V. Joshi , Mary Tagliaferri , Werner Rubas , Saul Kivimae , Rhoneil L. Pena
CPC分类号： C07K16/2818 , C07K14/55
摘要： Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2Rβ-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.
-
28.发明公开公开(公告)号：US20230372500A1
公开(公告)日：2023-11-23
申请号：US18221300
申请日：2023-07-12
申请人： Nektar Therapeutics
发明人： Zhongxu Ren , Neel K. Anand , Haiying Cai , Bo-Liang Deng , Bhalchandra V. Joshi , Jonathan Zalevsky , Takahiro Miyazaki , Saul Kivimae
CPC分类号： A61K47/60 , A61K47/54 , A61K47/642 , A61P35/00 , A61K9/0029
摘要： Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I:
RQ-POLY-Xr-TLR7/8 AG)q Formula I
or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.-
公开(公告)号：US20220235056A1
公开(公告)日：2022-07-28
申请号：US17608582
申请日：2020-05-01
申请人： Nektar Therapeutics
发明人： Neel K. Anand , Natalia Aurrecoechea , Anthony James Brockway , Haiying Cai , Lin Cheng , Bo-Liang Deng , Donogh John Roger O'Mahony , Zhongxu Ren , Wen Zhang
IPC分类号： C07D487/04 , C07D519/00
摘要： The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of any one or more of the compounds described herein. In some embodiments, the subject has cancer and the method is a method of treating cancer.
-
公开(公告)号：US20210292425A1
公开(公告)日：2021-09-23
申请号：US16610401
申请日：2018-05-02
申请人： Nektar Therapeutics
发明人： Saul Kivimae , Marlene Hennessy , Neel K. Anand , Haiying Cai , Bo-Liang Deng , Zhongxu Ren , Bhalchandra V. Joshi
IPC分类号： C07K16/28 , C07K14/55 , A61K31/4745 , A61P35/00 , A61K47/60
摘要： Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.03 秒)
